Seattle Genetics Presents New Antibody-Drug Conjugate Data at AACRRandi Hernandez
编译:newborn 抗体药物偶联物(antibody-drug conjugate,ADC)是一类通过特定的连接头将靶标特异性的单克隆抗体与高杀伤性的细胞毒性药物偶联起来的靶向生物药剂,以单克隆抗体为载体将小分子细胞毒性药物以靶向方式高效地运输至目标肿瘤细胞中。辉瑞在2000年推出首款ADC药物Mylotarg之后,这类疗法凭借其高效的抗肿瘤效果被赋...
Trastuzumab deruxtecanis a human epidermal growth factor receptor 2 (HER2)-directed antibody and topoisomerase inhibitor conjugate. The new drug targets the HER2 protein and is linked to a topoisomerase inhibitor, which is cytotoxic. "There have been many advances in the development of drugs for H...
Basic composition of an antibody–drug conjugate (ADC) and its mechanisms of action. (1) ADCs are composed of four key components: the target antigen, an antibody construct, a payload (most commonly a cytotoxic agent), and a linker moiety that will couple the payload and the antibody. Once...
MCE 国际站:Toxins for Antibody-Drug Conjugate Research Library 品牌:MedChemExpress (MCE) 货号:HY-L023 中文名称:抗体偶联药物毒素分子库 存储条件:-80°C 运输条件:蓝冰或干冰 产品活性:抗体偶联药物 (ADCs) 是由单克隆抗体、连接剂和细胞毒素组成的一类新型癌症治疗药物。到目前为止,已经有多种 ADC 药物通...
Data highlights potential of Hummingbird Bioscience’s dual-payload antibody-drug conjugate platform to improve upon the current generation of ADCs
Table 4. Trials of antibody-drug conjugate-immune checkpoint inhibitors in urothelial carcinoma NCT>Trial NameAgentStudy PopulationSample SizeStudy PhasePrimary or Co-Primary EndpointsORR (CR)DCRPFSOSTRAE, Grades 1 to 4TRAE, ≥ Grade 3Citation HER-2-Targeting ADCs NCT04264936 RC48-C014 RC48+To...
antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologicsTM, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 ...
Multifunctional HER2-antibody conjugated polymeric nanocarrier-based drug delivery system for multi-drug-resistant breast cancer therapy. conjugate herceptin (antibody) with PLGA NPs for promoting the site-specific intracellular delivery of Tam against HER2 receptor overexpressed breast cancer (... R Vivek...
The antibody-drug conjugate (ADC) was turned down by NICE in draft guidance published earlier this year, leading to concerns of a disparity in access to the drug as the Scottish Medicines Consortium (SMC) had already cleared its use. Breast Cancer Now – which launched a petition to try to...